Content about hepatitis B

November 8, 2011
FDA develops Web resource outlining proper sharps disposal

The Food and Drug Administration on Tuesday launched a website for patients and caregivers on the safe disposal of needles and other “sharps” that are used at home, at work and while traveling.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday launched a website for patients and caregivers on the safe disposal of needles and other “sharps” that are used at home, at work and while traveling.

October 27, 2011
Dynavax releases results of hepatitis B vaccine phase-3 trial

An experimental vaccine for hepatitis B made by Dynavax Technologies appears to work better in patients with diabetes than current treatments, the company said.

BERKELEY, Calif. — An experimental vaccine for hepatitis B made by Dynavax Technologies appears to work better in patients with diabetes than current treatments, the company said.

October 3, 2011
Bristol-Myers Squibb to present at The Liver Meeting

Bristol-Myers Squibb will present 22 study abstracts next month at the 62nd annual meeting of the American Association for the Study of Liver Diseases in San Francisco, the company said.

PRINCETON, N.J. — Bristol-Myers Squibb will present 22 study abstracts next month at the 62nd annual meeting of the American Association for the Study of Liver Diseases in San Francisco, the company said.

Key presentations set to take place at the meeting, called The Liver Meeting, include studies on the hepatitis B drug Baraclude (entecavir) and drugs under development for hepatitis C and liver cancer.

July 25, 2011
New drugs to alter HCV treatment, outcomes

A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.


October 17, 2010
FDA OKs expanded use of Baraclude

The Food and Drug Administration has approved an additional use for a hepatitis drug....

PRINCETON, N.J. The Food and Drug Administration has approved an additional use for a hepatitis drug.

 

Bristol-Myers Squibb announced Monday the approval of Baraclude (entecavir) as a treatment for chronic hepatitis B in adults with decompensated liver disease. The drug already is approved for adults with evidence of active viral replication.

 

 

March 18, 2010
NHVR: Increased funding needed for viral hepatitis screening, intervention

“Systemic underfunding” at the Centers for Disease Control and Prevention’s Division of Viral Hepatitis puts...

WASHINGTON “Systemic underfunding” at the Centers for Disease Control and Prevention’s Division of Viral Hepatitis puts the health of millions of Americans with viral hepatitis at risk, a group of organizations focused on the disease said this week.